AAO

Novel glasses, designed for children with cranial dysotosis, help doctors provide functional eyewear for children in underserved communities, says Donny Suh, MD.

David Hutton discusses the AAO 2022 presentation, "Corneal Edema, Opacifications, Ectasia, and Bacterial Keratitis: Diagnosis and Treatment Strategies from the Preferred Practice Pattern Guidelines," with speaker Francis S. Mah, MD.

During a presentation at the American Academy of Ophthalmology’s 2022 annual meeting at McCormick Place in Chicago, Maria A. Guzman Aparicio, MD, and Teresa C. Chen, MD, detailed their research that found that pediatric patients have a significantly higher incidence of new-onset strabismus after tube shunt surgery for glaucoma compared with adults.

Mark Packer, MD, speaks on his 2022 AAO poster: "Safety and Effectiveness of a New FDA-Approved Dispersive Ophthalmic Viscosurgical Device."

Ben Bergo, CEO of Visus Therapeutics, announced the acquisition of all patents and other assets of ViewPoint Therapeutics, which will accelerate development of novel alpha-crystallin chaperone compounds as a non-surgical treatment for age-related cataracts.

Roger A. Goldberg, MD, MBA, discusses his 2022 AAO poster: "T&E-Based Personalized Treatment Interval Dynamics in the YOSEMITE/RHINE Trials of Faricimab in DME."

CXL Ophthalmics Inc. on Thursday published results of the EpiSmart cross-linking Phase 2 study for keratoconus.

At the American Academy of Ophthalmology annual meeting in Chicago, Gautam Kamthan, MD, discussed the feasibility of robot-assisted ophthalmic gonio-surgery.

Results from our recent poll regarding AAO 2022 attendance indicate that most ophthalmologists and retina specialists plan to participate in the Annual Meeting in person in Chicago, Illinois.

We're polling ophthalmologists about attendance at the 2022 American Academy of Ophthalmology Meeting in Chicago, Illinois. The poll is now closed.

The American Academy of Ophthalmology annual meeting is coming to Chicago, Illinois from September 30 to October 3, featuring Subspecialty Days and a virtual component. The event will be held at Chicago’s McCormick Place, billed as the largest convention center in North America and located on the shore of Lake Michigan.

Lisa Nijm, MD, advises young ophthalmologists on how to find common ground with their preferred practice and find solutions in the negotiation process that will help both parties flourish.

Dr. Raymond Douglas discusses the real-world adherence to teprotumumab as a treatment for thyroid eye disease.

Dr. Quan Dong Nguyen reviews a Monte Carlo simulation that showed evidence that treating severe NPDR with anti-VEGF therapy garners positive results.

Dr. Katherine Talcott discusses baseline factors—CST thickness, hemoglobin A1C, and baseline vision—and their effects on DME resolution.

Lisa Nijm, MD, discusses how utilizing a dexamethasone intracanalicular insert after cataract surgery saves time for practices.

Preeya Gupta, MD, walks through her four pearls for successful corneal collagen cross-linking, including handling patient expectations, managing the epithelial cells and preventing infectious keratitis.

Firas Rahhal, MD, discusses Outlook Therapeutics’ Phase 3 pivotal NORSE TWO trial for ONS-5010.

Ted Leng, MD, discusses his IRIS Registry analysis presentation regarding variations in vitreoretinal physician utilization of ancillary testing.

Robert J. Noecker, MD, MBA, discusses the IRIDEX consensus paper regarding MicroPulse transscleral therapy for glaucoma at AAO 2021.

At AAO, AbbVie presented results from the ARTEMIS study, showcasing IOP lowering that extends beyond the original 20-month timeframe.

Jill Hopkins, MD, discusses results from phase 3a of the Merlin trial for brolucizumab as a treatment for wet AMD and provides updates on KESTREL and KITE trials for the treatment of diabetic macular edema.

At the 2021 American Academy of Ophthalmology annual meeting, Penny Asbell, MD, FACS, MBA, discussed data from the ARMOR study and its effects on treating ophthalmic infections, such as endophthalmitis.

New cell therapy drug makes treatment of corneal endothelial disease more accessible.

Jay Duker, MD, discusses EYP-1901, EyePoint Pharmaceuticals’ sustained-release anti-VEGF drug for the treatment of wet AMD.

At AAO 2021, Aerie Pharmaceuticals presented the results of their phase 2b clinical trial of AR-15512, a triple 8 antagonist, for the treatment of dry eye.

Mohamed Abou Shousha, MD, PhD, discusses Heru’s wearable AI-powered diagnostic devices at AAO 2021.

Verana Health showcases the VeraQ quality measures dashboard for the IRIS registry report at AAO 2021.

A brief overview of the plethora of findings presented at the 2021 American Academy of Ophthalmology meeting held November 12-15 in New Orleans, LA.

Mark Wieland, MD, explores how Port Delivery System with ranibizumab provides drug delivery over an extended period.